Measuring the constitutive activation of c-Jun N-terminal kinase isoforms

Methods in Enzymology

Volumn 484, Issue C, 2010, Pages 531-548

  Nitta, Ryan T ^a   Badal, Shawn S ^b   Wong, Albert J ^a,b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; HOMODIMER; RADIOISOTOPE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1ALPHA1; STRESS ACTIVATED PROTEIN KINASE 1ALPHA2; STRESS ACTIVATED PROTEIN KINASE 1BETA1; STRESS ACTIVATED PROTEIN KINASE 1BETA2; STRESS ACTIVATED PROTEIN KINASE 2ALPHA1; STRESS ACTIVATED PROTEIN KINASE 2ALPHA2; STRESS ACTIVATED PROTEIN KINASE 2BETA1; STRESS ACTIVATED PROTEIN KINASE 2BETA2; STRESS ACTIVATED PROTEIN KINASE 3ALPHA1; STRESS ACTIVATED PROTEIN KINASE 3ALPHA2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

AUTOPHOSPHORYLATION; BOOK; CANCER CELL; CARCINOGENESIS; CARCINOGENICITY; CELL GROWTH; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FIBROBLAST; GENETIC TRANSFECTION; GLIOMA; IMMUNOFLUORESCENCE; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

MUS;

EID: 78049297451     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381298-8.00026-5     Document Type: Chapter

References (45)

1. Adachi M., Fukuda M., Nishida E. Two co-existing mechanisms for nuclear import of MAP kinase: Passive diffusion of a monomer and active transport of a dimer. EMBO J. 1999, 18:5347-5358.
2. Bain J., McLauchlan H., Elliott M., Cohen P. The specificities of protein kinase inhibitors: An update. Biochem. J. 2003, 371:199-204.
3. Bode A.M., Dong Z. The functional contrariety of JNK. Mol. Carcinog. 2007, 46:591-598.
4. Bogoyevitch M.A. The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): Differences revealed by gene targeting. Bioessays 2006, 28:923-934.
5. Chen N., Nomura M., She Q.B., Ma W.Y., Bode A.M., Wang L., Flavell R.A., Dong Z. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res. 2001, 61:3908-3912.
6. Chen Z., Gibson T.B., Robinson F., Silvestro L., Pearson G., Xu B., Wright A., Vanderbilt C., Cobb M.H. MAP kinases. Chem. Rev. 2001, 101:2449-2476.
7. Chow C.W., Rincon M., Cavanagh J., Dickens M., Davis R.J. Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science 1997, 278:1638-1641.
8. Cuenda A. Mitogen-activated protein kinase kinase 4 (MKK4). Int. J. Biochem. Cell Biol. 2000, 32:581-587.
9. Cuevas B.D., Abell A.N., Johnson G.L. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 2007, 26:3159-3171.
10. Cui J., Han S.Y., Wang C., Su W., Harshyne L., Holgado-Madruga M., Wong A.J. c-Jun NH(2)-terminal kinase 2alpha2 promotes the tumorigenicity of human glioblastoma cells. Cancer Res. 2006, 66:10024-10031.
11. Cui J., Holgado-Madruga M., Su W., Tsuiki H., Wedegaertner P., Wong A.J. Identification of a specific domain responsible for JNK2alpha2 autophosphorylation. J. Biol. Chem. 2005, 280:9913-9920.
12. Davis R.J. Signal transduction by the c-Jun N-terminal kinase. Biochem. Soc. Symp. 1999, 64:1-12.
13. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
14. Ford J., Ahmed S., Allison S., Jiang M., Milner J. JNK2-dependent regulation of SIRT1 protein stability. Cell Cycle 2008, 7:3091-3097.
15. Gaits F., Russell P. Active nucleocytoplasmic shuttling required for function and regulation of stress-activated kinase Spc1/StyI in fission yeast. Mol. Biol. Cell 1999, 10:1395-1407.
16. Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H.K., Derijard B., Davis R.J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 1996, 15:2760-2770.
17. Gupta S., Campbell D., Derijard B., Davis R.J. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995, 267:389-393.
18. Holzberg D., Knight C.G., Dittrich-Breiholz O., Schneider H., Dorrie A., Hoffmann E., Resch K., Kracht M. Disruption of the c-JUN-JNK complex by a cell-permeable peptide containing the c-JUN delta domain induces apoptosis and affects a distinct set of interleukin-1-induced inflammatory genes. J. Biol. Chem. 2003, 278:40213-40223.
19. Ishii M., Suzuki Y., Takeshita K., Miyao N., Kudo H., Hiraoka R., Nishio K., Sato N., Naoki K., Aoki T., Yamaguchi K. Inhibition of c-Jun NH2-terminal kinase activity improves ischemia/reperfusion injury in rat lungs. J. Immunol. 2004, 172:2569-2577.
20. Kallunki T., Deng T., Hibi M., Karin M. c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 1996, 87:929-939.
21. Ke H., Harris R., Coloff J.L., Jin J.Y., Leshin B., de Marval P.M., Tao S., Rathmell J.C., Hall R.P., Zhang J.Y. The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia. Cancer Res. 2010, 70(8):3080-3088.
22. Khatlani T.S., Wislez M., Sun M., Srinivas H., Iwanaga K., Ma L., Hanna A.E., Liu D., Girard L., Kim Y.H., Pollack J.R., Minna J.D., et al. c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene 2007, 26:2658-2666.
23. Khokhlatchev A.V., Canagarajah B., Wilsbacher J., Robinson M., Atkinson M., Goldsmith E., Cobb M.H. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell 1998, 93:605-615.
24. Kim E.K., Choi E.J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta 2010, 1802:396-405.
25. Li J.Y., Wang H., May S., Song X., Fueyo J., Fuller G.N., Wang H. Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas. J. Neurooncol. 2008, 88:11-17.
26. Maeda S., Karin M. Oncogene at last-c-Jun promotes liver cancer in mice. Cancer Cell 2003, 3:102-104.
27. McCubrey J.A., Lahair M.M., Franklin R.A. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid. Redox Signal. 2006, 8:1775-1789.
28. Minden A., Lin A., Claret F.X., Abo A., Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 1995, 81:1147-1157.
29. Nielsen C., Thastrup J., Bottzauw T., Jaattela M., Kallunki T. c-Jun NH2-terminal kinase 2 is required for Ras transformation independently of activator protein 1. Cancer Res. 2007, 67:178-185.
30. Nitta R.T., Chu A.H., Wong A.J. Constitutive activity of JNK2 alpha2 is dependent on a unique mechanism of MAPK activation. J. Biol. Chem. 2008, 283:34935-34945.
31. Oleinik N.V., Krupenko N.I., Krupenko S.A. Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway. Oncogene 2007, 26(51):7222-7230.
32. Olson M.F., Ashworth A., Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 1995, 269:1270-1272.
33. Pimienta G., Ficarro S.B., Gutierrez G.J., Bhoumik A., Peters E.C., Ronai Z., Pascual J. Autophosphorylation properties of inactive and active JNK2. Cell Cycle 2007, 6:1762-1771.
34. Rennefahrt U.E., Illert B., Kerkhoff E., Troppmair J., Rapp U.R. Constitutive JNK activation in NIH 3T3 fibroblasts induces a partially transformed phenotype. J. Biol. Chem. 2002, 277:29510-29518.
35. Shaw D., Wang S., Villasenor A.G., Tsing S., Walter D., Browner M., Barnett J., Kuglstatter A. The crystal structure of JNK2 reveals conformational flexibility in the MAP kinase insert and indicates its involvement in the regulation of catalytic activity. J. Mol. Biol. 2008, 20(17):5217-5220.
36. Stebbins J.L., De S.K., Machleidt T., Becattini B., Vazquez J., Kuntzen C., Chen L.H., Cellitti J.F., Riel-Mehan M., Emdadi A., Solinas G., Karin M., Pellecchia M. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc. Natl. Acad. Sci. USA 2008, 105:16809-16813.
37. Torii S., Yamamoto T., Tsuchiya Y., Nishida E. ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci. 2006, 97:697-702.
38. Tsuiki H., Tnani M., Okamoto I., Kenyon L.C., Emlet D.R., Holgado-Madruga M., Lanham I.S., Joynes C.J., Vo K.T., Wong A.J. Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Cancer Res. 2003, 63:250-255.
39. Wang M., Atayar C., Rosati S., Bosga-Bouwer A., Kluin P., Visser L. JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125. J. Pathol. 2009, 218:95-103.
40. Wilsbacher J.L., Juang Y.C., Khokhlatchev A.V., Gallagher E., Binns D., Goldsmith E.J., Cobb M.H. Characterization of mitogen-activated protein kinase (MAPK) dimers. Biochemistry 2006, 45:13175-13182.
41. Wu X., Tu X., Joeng K.S., Hilton M.J., Williams D.A., Long F. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell 2008, 133:340-353.
42. Xie X., Gu Y., Fox T., Coll J.T., Fleming M.A., Markland W., Caron P.R., Wilson K.P., Su M.S. Crystal structure of JNK3: A kinase implicated in neuronal apoptosis. Structure 1998, 6:983-991.
43. Xu X., Heidenreich O., Kitajima I., McGuire K., Li Q., Su B., Nerenberg M. Constitutively activated JNK is associated with HTLV-1 mediated tumorigenesis. Oncogene 1996, 13:135-142.
44. Yang R., Trevillyan J.M. c-Jun N-terminal kinase pathways in diabetes. Int. J. Biochem. Cell Biol. 2008, 40:2702-2706.
45. Yang Y.M., Bost F., Charbono W., Dean N., McKay R., Rhim J.S., Depatie C., Mercola D. C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin. Cancer Res. 2003, 9:391-401.